Looking back at EGFR-targeted pills for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks back at how people with non-small cell lung cancer (NSCLC) were treated with EGFR-targeted medicines (gefitinib, erlotinib, and osimertinib). It may help doctors understand which patients benefit most and what side effects to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have NSCLC confirmed by lab testing (tissue or cell proof)
- Have a good enough day-to-day ability level (ECOG score 0 to 2)
- Have blood counts, kidney, and liver function that are adequate
- Have no uncontrolled major health problems and no active lung scarring/inflammation (interstitial lung disease)
- Not be on other chemotherapy at the time the study records were made
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
Hear when a new EGFR-TKI Resistant Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.